Epigenomics AGFRA:ECX 13 FCF Margin % is -1,785.00% as of Dec. 2025. GuruFocus rates FRA:ECX with a GF Score™ of 13/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Epigenomics AG ranks worse than 95.57% on this metric.
The historical rank and industry rank for Epigenomics AG's FCF Margin % or its related term are showing as below:
FRA:ECX'
s FCF Margin % Range Over the Past 10 Years
Min: -2220.83 Med: -1139.19 Max: -67.5
Current: -2220.83
During the past 13 years, the highest FCF Margin % of Epigenomics AG was -67.50%. The lowest was -2220.83%. And the median was -1139.19%.
FRA:ECX's FCF Margin % is ranked worse than 95.57% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.89
vs FRA:ECX: -2220.83
Epigenomics AG FCF Margin % Related Terms
Epigenomics AG FCF Margin % Historical Data
* Premium members only.
The historical data trend for Epigenomics AG's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ECX vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Epigenomics AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigenomics AG (FRA:ECX) has a FCF Margin % of -1,785.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Epigenomics AG and its competitors. According to the industry distribution chart, Epigenomics AG ranks #194 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 95.6%.
Is Epigenomics AG's FCF Margin % too high?
Epigenomics AG's current FCF Margin % is -1,785.00%. Based on the distribution chart, Epigenomics AG ranks #194 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Epigenomics AG has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #194 out of 203 companies for FCF Margin %. This places Epigenomics AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Epigenomics AG and its competitors. Epigenomics AG's current FCF Margin % is -1,785.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.87 — trading 866.7% above its estimated fair value. The current FCF Margin % is -1,785.00%. Epigenomics AG's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current FCF Margin % is -1,785.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.87 is trading 866.7% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
FCF Margin %: -1,785.00%
GF Value™: €0.09 vs. price of €0.87 (866.7% above fair value)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
13GF Score
Get the complete analysis for FRA:ECX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
